- 1 Title (92/100 characters with spaces): Interim influenza vaccine effectiveness
- 2 estimates during the 2023 Southern Hemisphere season
- 3
- 4 Subtitle (58/60 characters with spaces): Influenza vaccine effectiveness in Lima,
- Peru, 2023 5
- 6
- 7 Authors:
- 8 (1) J Gonzalo Acevedo-Rodriguez, MD
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana 9
- 10 Cayetano Heredia, Lima, Perú
- 11 (2) Carlos Zamudio, MD
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana 12
- 13 Cayetano Heredia, Lima, Perú
- 14 (3) Noah Kojima, MD
- 15 Centers for Disease Control and Prevention, Atlanta, Georgia, U.S.A
- (4) Fiorella Krapp, MD, MSc 16
- 17 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana
- Cayetano Heredia, Lima, Perú 18
- 19 (5) Pablo Tsukayama, PhD, MSc
- 20 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana
- 21 Cayetano Heredia, Lima, Perú
- 22 (6) C Stefany Neciosup-Vera, MSc
- 23 Departamento de Ciencias, Pontificia Universidad Católica del Perú, Lima, Perú

- 24 (7) Eduardo Gotuzzo, MD, FACP, FIDSA
- 25 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana
- 26 Cayetano Heredia, Lima, Perú
- 27 (8) and the PISAAC working group authors (Elsa González, Giancarlo Sal y Rosas,
- 28 Ericka Meza, Paula Arribas, Francesca Ginocchio, Flavia Morán, Renato Cava, Roberto
- 29 Freire-Esteves, Laura Castro, Ashley Fowlkes, and Eduardo Azziz-Baumgartner).

30

31 **Keywords:** Influenza; Incidence, Lineage, Vaccine effectiveness; Peru

32

33 Corresponding Author Contact Information: J Gonzalo Acevedo-Rodriguez, MD.

34 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano

35 Heredia, Av. Honorio Delgado 430, San Martin de Porres, 15102, Lima-Peru

- 36 (juan.acevedo@upch.pe).
- 37

## 38 Abstract

39 Our findings suggest that a substantial number of people sought care for CLI during an

40 early Southern Hemisphere season during which A/H1N1pdm09 clade 6B.1A.5a.2a

- 41 viruses predominated. The minority vaccinated benefitted from the A/Victoria/2570/2019
- 42 (H1N1)pdm09-like antigen which afforded good protection against illness.

43

## 44 Main Text

45 Evaluations of vaccine effectiveness (VE) against influenza in the Southern 46 Hemisphere (SH) can assist that region of the world and provide insights into the 47 anticipated performance of Northern Hemisphere (NH) vaccines.<sup>1,2</sup> Using population48 based surveillance data for COVID-19, we estimated VE against medically attended
49 influenza in Lima, Peru.

50 From January 1 to July 31, 2023, our population-based surveillance identified 51 patients seeking care at two primary health centers in San Juan de Lurigancho, Lima. 52 Patients presenting with COVID-19-like illness (CLI, defined as onset ≤7 days of ≥2 53 signs or symptoms, e.g., documented or reported fever, chills, rigors, myalgia, 54 headache, and sore throat) were asked for written consent to participate. Enrolled 55 participants reported preexisting condition and influenza vaccine histories and provided 56 nasopharyngeal swabs for influenza virus and SARS-CoV-2 testing through multiplex qPCR.<sup>3</sup> Whole-genome sequencing was conducted for positive specimens with a cycle 57 58 threshold value ≤25 using the Illumina Respiratory Virus Panel.

59 Incidence of medically attended influenza illness was estimated by dividing the 60 number of patients with CLI that consented to participate by the population assigned to 61 the health centers (i.e., 91,801) and adjusting for enrollment (supplement). Patients who 62 self-reported influenza vaccination from May 2022 until >14 days before enrollment were classified as vaccinated. VE against medically attended influenza was calculated 63 using a test-negative design.<sup>4</sup> Cases were defined as patients with a test-positive for 64 65 influenza by qPCR test and controls as patients test-negative for both influenza and 66 SARS-CoV-2. The study was approved by the institutional review board of Universidad Peruana Cayetano (PRISA repository: El0002439) Centers for Disease Control and 67 Prevention non-research determination 0900f3eb81ecbe9f. 68

69 During study period, 923 (13.9%) of 6,660 persons who sought outpatient care 70 met criteria for CLI, and 567 (61.4%) were enrolled and had testing for influenza viruses 71 and SARS-COV-2 (Table 1). Influenza was detected in 106 (18.7%) as early as January. 72 months before the historical May start of influenza seasons in Lima (Figure 1). Seventy-73 nine (75%) patients with CLI tested-positive for influenza A and 27 (25%) for B. We 74 sequenced 32 influenza A specimens; 29 (90.6%) were A(H1N1)pdm09 clade 75 6B.1A.5a.2a (Table 1). The cumulative incidence of medically attended influenza per 76 1,000 population was 10.1 (95% confidence interval [95%CI]: 8.2–12.0) for influenza A 77 and 3.5 (95%CI: 2.3-4.6) for influenza B. Only 112 (19.7%) patients were vaccinated 78 against influenza. The age and month adjusted VE against medically attended influenza 79 was 65.1% (95%CI: 26.5-83.4); 58.2% (95%CI: 5.1-81.6) for influenza A and 77.6% 80 (95%CI: 0-95.5) for B.

81 During the 2023 SH season, a substantial number of people sought care for 82 influenza, but incidence was lower than reported among persons seeking care for influenza-like illness from before COVID-19.<sup>5</sup> 2023 SH VE against influenza was similar 83 to that of the 2022 SH season<sup>1,2</sup> and the 2022-2023 U.S. season<sup>6</sup> even though 84 A(H1N1)pdm09 clade 6B.1A.5a.2a viruses predominated in 2023 whereas influenza 85 A(H3N2) clade 2.a3 viruses predominated in 2022.<sup>7</sup> The A/Victoria/2570/2019 86 87 (H1N1)pdm09-like virus in the SH vaccine conferred a 65% risk reduction in medically 88 attended influenza, yet fewer than one in five persons in this evaluation reported 89 receiving an influenza vaccine during 2023.

Our findings are subject to limitations. First, in the absence of healthcare
 utilization surveys, it is unclear if the population assigned to our clinics always sought

92 care there versus other clinics. Second, only half of specimens had cycle threshold

- 93 value ≤25; thus, it is possible that we missed clades. Finally, confounding might remain
- 94 in our analysis despite our statistical models.
- 95 In conclusion, our findings suggest that mostly unvaccinated people sought care
- 96 early during SH season for illnesses predominantly attributable to A/H1N1pdm09 clade
- 97 6B.1A.5a.2a viruses. Persons vaccinated benefitted from the A/Victoria/2570/2019
- 98 (H1N1)pdm09-like antigen, which afforded good protection against illness. If the same
- 99 viruses predominate in the NH, our estimates of 2023 SH influenza vaccine
- 100 effectiveness suggest that 2023-2024 NH influenza vaccines, which include a similar
- 101 strain composition, could provide similar protection during the upcoming influenza
- 102 season.
- 103
- 104 **Declarations:**
- 105 None.
- 106 Funding:
- 107 This study was supported by the Centers for Disease Control and Prevention
- 108 cooperative agreement award GH00266.
- 109 **Disclaimer:**
- 110 The findings and conclusions in this report are those of the authors and do not
- 111 necessarily represent the official position of the Centers for Disease Control and
- 112 Prevention.
- 113 Author Contribution:

- 114 CZ and EG had full access to all the data in the study and take responsibility for the
- integrity of the data and the accuracy of the data analysis. Data will be shared by
- 116 contacting the corresponding author upon request for research purposes. JGA-R, CZ,
- 117 FK, FM, PT and EG conceived and designed the study, EM coordinated laboratory
- analysis, PT performed genomic sequencing, PA, FG and RC coordinated data
- 119 collection and management, CSN-V and GSR performed the statistical analysis. All
- 120 authors wrote and approved the final manuscript. NK and EGL helped draft, edit and
- 121 review the manuscript. LC, AF and EAB helped interpret findings and edit the
- 122 manuscript.
- 123 Acknowledgements:
- 124 None

## 125 **References**

- 126 1. Chard AN, Nogareda F, Regan AK, et al. End-of-season influenza vaccine
- 127 effectiveness during the Southern Hemisphere 2022 influenza season Chile,
- 128 Paraguay, and Uruguay. Int J Infect Dis. Sep 2023;134:39-44.
- 129 doi:10.1016/j.ijid.2023.05.015
- 130 2. Olivares Barraza MF, Fasce RA, Nogareda F, et al. Influenza Incidence and
- 131 Vaccine Effectiveness During the Southern Hemisphere Influenza Season Chile, 2022.
- 132 *MMWR Morb Mortal Wkly Rep.* Oct 28 2022;71(43):1353-1358.
- 133 doi:10.15585/mmwr.mm7143a1
- 134 3. Nagy A, Černíková L, Kunteová K, et al. A universal RT-qPCR assay for "One
- Health" detection of influenza A viruses. *PloS one*. 2021;16(1):e0244669.
- 136 doi:10.1371/journal.pone.0244669
- 137 4. Jackson ML, Nelson JC. The test-negative design for estimating influenza
- 138 vaccine effectiveness. *Vaccine*. Apr 19 2013;31(17):2165-8.
- 139 doi:10.1016/j.vaccine.2013.02.053
- 140 5. Tinoco YO, Azziz-Baumgartner E, Uyeki TM, et al. Burden of Influenza in 4
- 141 Ecologically Distinct Regions of Peru: Household Active Surveillance of a Community
- 142 Cohort, 2009-2015. Clin Infect Dis. Oct 16 2017;65(9):1532-1541.
- 143 doi:10.1093/cid/cix565
- 144 6. McLean HQ, Petrie JG, Hanson KE, et al. Interim Estimates of 2022–23
- 145 Seasonal Influenza Vaccine Effectiveness Wisconsin, October 2022–February 2023.
- 146 MMWR Morbidity and Mortality Weekly Report. 2023;72(8):201-205.
- 147 doi:10.15585/mmwr.mm7208a1

- 148 7. GISAID. Real-time tracking of influenza A/H3N2 evolution. 7 Sep 2023,
- 149 https://gisaid.org/database-features/influenza-genomic-epidemiology/

151 Table 1. Influenza test results and seasonal vaccination status among patients presenting in two primary care centers with

152 COVID-19-like illness in Lima, Peru, by selected characteristics (N = 567), January–May 2023

	Enrolled Patients			Influenza test result, no. (%)		
		No. (row %)	. +	D 1/1	N //	p- ,
Characteristic	Total no.	vaccinated*	p-value'	Positive	Negative	value'
Overall	567	112 (19.7)	—	106 (18.7)	461 (81.3)	_
Age in years						
<5	100	29 (29.0)	0.007	6 (6.0)	94 (94.0)	< 0.005
5 – 59	407	67 (16.5)		93 (22.9)	314 (77.1)	
≥60	60	16 (26.7)		7 (11.7)	53 (88.3)	
Preexisting conditions <sup>§</sup>						
One or more condition	116	22 (19.0)	0.91	20 (17.2)	96 (82.8)	0.75
No preexisting conditions	451	90 (20.0)		86 (19.1)	365 (80.9)	
Sex				<u> </u>		
Male	207	41 (19.8)	1	48 (23.2)	159 (76.8)	0.05
Female	360	71 (19.7)		58 (16.1)	302 (83.9)	
Influenza test result						
Negative	461	102 (22.1)			—	
Influenza (any)	106	10 (9.4)	<0.005			
Influenza A	79	8 (10.1)	0.03			
Influenza B	27	2 (7.4)	0.13			
Influenza sequence result						
Tested	50	3 (6.0)	0.08			
A(H1N1) clade 6B.1A.5a.2a	29	0 (0)	1			
A(H3N2) clade 3C.2a1b.2a.2a.3	3	0 (0)				
B/Victoria clade V1A.3a.2	9	2 (22.3)				

153

- <sup>154</sup> \*Vaccinated: defined as self-reported influenza vaccination from May 2022 until >14 days before enrolment. Self-reporting
- 155 was used because seasonal influenza immunization is not routinely entered in the national electronic registry.
- 156 Nevertheless, we could verify the exact date of vaccination for 87/112 participants and 19 more recalled the month and
- 157 year of vaccination. According to these data, 96/112 received the 2022 vaccine (May 2022 Apr2023) and 10/112 received
- the 2023 vaccine. For 6/112, it was unknown if they received the 2022 or the 2023 seasonal vaccine because timing of
- 159 vaccination was not ascertained.
- <sup>160</sup> <sup>†</sup>Tested using chi square with a significance level of p<0.05. Fisher exact test was used when an expected value was less
- 161 than 5.
- <sup>162</sup> <sup>§</sup> Preexisting conditions: pregnancy, diabetes mellitus, hypertension, asthma, chronic hepatopathy, chronic neurological,
- 163 hematological, pulmonary or renal disease, immunodeficiency (including HIV), cardiovascular or cerebrovascular disease,
- 164 cancer, Down syndrome and other relevant conditions.
- 165

- 166 Figure 1: Weekly laboratory-confirmed incident influenza cases and positivity rate at two primary care health centers from
- 167 patients who presented with COVID-19-like illness in Lima, Peru, January–May 2023

